Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07288801

Vitamin D for Preventing Recurrent Preeclampsia in Pregnant Women

The goal of this clinical trial is to find out whether giving vitamin D to pregnant women who had pre-eclampsia in a previous pregnancy helps prevent the condition from coming back. The main question it aims to answer is:

Does vitamin D supplementation reduce the chance of pre-eclampsia recurring in pregnant women with a history of pre-eclampsia?

To answer this question, pregnant women attending the antenatal clinic at the Department of Obstetrics and Gynaecology, Nishtar Hospital Multan will be invited to join the study.

Participants will be randomly assigned to two equal groups:

* Vitamin D group: will take 4,000 IU of oral vitamin D until 36 weeks of gestation. * Placebo group: will receive a pill identical in appearance, taste, and consistency but without vitamin D.

While on the study medication, each woman will visit the clinic every two weeks. At each visit, her blood pressure will be measured, and if it is 140/90 mmHg or higher, a urine test will check for protein to identify pre-eclampsia as per hospital protocol. Any diagnosis of pre-eclampsia will lead to standard care, and the outcome will be recorded.

At the end, researchers will compare how many women in each group developed recurrent pre-eclampsia.

This study will help answer whether vitamin D supplementation can safely reduce the risk of pre-eclampsia returning in women with a prior history - a question important for improving pregnancy outcomes and maternal health.

Recruiting

Interested in participating?

Request Info

Key information

Age range

20 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Nishtar Medical University and Hospital

Multan, Punjab Province, 60000, Pakistan

Location status: Recruiting

Location contact

Mehnaz K Professor, FCPS

CONTACT

[email protected]

+92 333 6131713

Tehseen A Principal Investigator, MBBS

CONTACT

[email protected]

+92 303 7832417

Tehseen A Principal Investigator, MBBS

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Gestational age ≥ 20-weeks (on LMP method) ' - Past medical history of pre-eclampsia

Exclusion criteria

  • Pre-existing hypertension, cardiac diseases, renal disease, thyrotoxicosis (on history and medical record)
  • Women presenting with intra-uterine death of the fetus.

Treatment and study plan

Vitamin D

Drug

4000 IU of vitamin D will be given orally, once daily till 36-weeks of gestation

Placebo and standard of care

Drug

Look, smell and taste alike oil emulsion drops, same number, till 36-weeks of gestation

Other names: Placebo

Primary outcomes

  1. Pre-eclampsia

    Time frame: From enrollment till 36 completed weeks of gestation

    Pregnant women, ≥ 20-weeks of gestation (on LMP method) having blood pressure of ≥140/90 mm of Hg plus protein (+1 or higher) in spot urine examination by dipstick method

Study contacts

Contact information is provided by the study sponsor or research team.

Tehseen A Principal Investigator, MBBS

CONTACT

[email protected]

+92 303 7832417

Sponsors and collaborators

Lead sponsor

Nishtar Medical University

Other

Registry information

Official study title

Role of Vitamin D in Prevention of Preeclampsia Recurrence in Pregnant Women With Previous History of Preeclampsia: A Randomized Controlled Trial

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 17, 2025
Registry last updated
Dec 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.